INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Not for submission under 37 CFR 1.99)

Application Number		10568488				
Filing Date		2006-02-14				
First Named Inventor Mo		9				
Art Unit		1635				
Examiner Name	To Be	Determined	Terra	c.	Gibbs	
Attorney Docket Number		ISPH-0859US	SA .			

					U.S.	PATENTS			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue (Date	Name of Pate of cited Docu	entee or Applicant Iment	Rele	es,Columns,Lines where vant Passages or Relevant res Appear
	1	5801154		1998-09	9-01	Baracchini et a	al.		
	2	6140124		2000-16	0-31	Monia et al.			
	3	6448079		2002-09	9-10	Monia et al.			
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		
Examiner Cite Initial* No Publication Number Code1 Publication Date Name of Patentee or of cited Document							Rele	s,Columns,Lines where vant Passages or Relevant es Appear	
	1	20030176383	A1	2003-09	⊋ 18	Monia et al.			
	2	20040171566	A1	2004-09) -02	Monia et al.			
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Add	d butto	ın.
				FOREIG	GN PAT	ENT DOCUM	ENTS		
Examiner Initial*	Examiner Cite Foreign Document Country Kind					Publication Date	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant

Figures Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10568488					
Filing Date	2006-02-14						
First Named Inventor Monia Art Unit		1					_
		1635					_
Examiner Name To Be		Determined	Terra	c.	Gibbs		_
Attornay Docket Numb	or	ISPH-0850LIS	Δ				_

	1	9835978	wo	A1	1998-08-20	Isis Pharmaceuticals					
	7	9960166	wo	A1	1999-11-25	Isis Pharmaceuticals					
If you wis	h to a	dd additional Foreign P	atent Document	citation	information p	lease click the Add butto	n	-			
			NON-PATE	NT LITE	ERATURE DO	CUMENTS					
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc),	the article (when approp date, pages(s), volume-is		T 5			
	1	AGRAWAL, S. et al., "Antisense therapeutics: is it as simple as complementary base recognition?" Molecular Medicine Today (2000) 6:72-81.									
	2	AOSHIBA, K. et al., "Role of p38-Mitogen-Activated Protein Kinase in Spontaneous Apoptosis of Human Neutrophilis," J. Immunol. (1999) 162:1692-1700. ARIMA, H. et al., "Specific Inhibition of Nitric Oxide Production in Macrophages by Phosphorothioate Antisense Oligonucleotides," J. Pharm. Sci. (1997) 86(10):1079-1084.									
	3										
	4	BRANCH, A. D., "A good antisense molecule is hard to find," TIBS (1998) 23:45-50.									
***	5	CHIALDA, L. et al., "Inhi production and mouse a				s differentially regulate costi (2005) 6:36.	mulated T cell cytokine				
	6	COHEN, P. S. et al., "Th (5):339-346.	e Critical Role of	p38 MAF	P Kinase in T Co	ell HIV-1 Replication," Molec	cular Medicine (1997) 3				
	7	CROOKE, S. T., "Basic Verlag, New York, pp. 1-		ense Th	erapeutics," Ant	isense Research and Appli	cation (1998) Springer-				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10568488						
Filing Date	2006-02-14						
First Named Inventor Mon		9					
Art Unit		1635					
Examiner Name To Be		Determined	Terra	c.	Gibbs		
Attorney Docket Number		ISPH-0859US	SA				

8	DATABASE EMBL:HS1208359 "zv28e08.s1 Soares. NhHMPu_S1 Homo sapiens cDNA clone IMAG:754790.3' similar to TR:G1304132 G1304132 TPRD.;, mRNA sequence," 4 May 1997 XP002302626 retrieved from EBI accession no. EM_EST:1206359 Database accession no. HS1206359.	
9	DUAN, W. et al., "Inhaled p38 Mitogen-Activated Protein Kinase Antisense Oligonucleotides Attenuates Asthma in Mice," Am. J. Respir. Crit. Care Med. (2005) 171:571-578.	
10	GREEN, D. W. et al., "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease," J. Am. Coll. Surg. (2000) 191:93-105.	
11	HAN, J. et al., "A MAP Kinase Targeted by Endotoxin and Hyperosmolarity in Mammalian Cells," Science (1994) 265:808-811.	
12	JEN, KY. et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells (2000) 18:307-319.	
13	KUMAR, R. K. et al., "Murine Model of Chronic Human Asthma," Immunology and Cell Biology (2001) 79:141-144.	
14	NAGATA, Y. et al., "Activation of p38 MAP Kinase and JNK But Not ERK is Required for Erythropoletin-Induced Erythroid Differentiation," Blood (1998) 92(6):1859-1869.	
15	NICK, J. A. et al., "Role of p38 Mitogen-Activated Protein Kinase in a Murine Model of Pulmonary Inflammation," J. Immunol. (2000) 164:2151-2159.	
16	NYCE, J. W., "Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases," Expert. Opin. Investig. Drugs (1997) 6(9):1149-1156.	
17	NYCE, J. W. et al., "DNA antisense therapy for asthma in an animal model," Nature (1997) 385(8618):721-725.	
18	RICHARDS, I. M., "Mouse models of allergic disease; how do they relate to asthma in man?" Clinical and Experimental Allergy (1996) 26:618-620.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10568488						
Filing Date	2008-02-14						
First Named Inventor Moni		1					
Art Unit		1635					
Examiner Name To Be		Determined	Terra	c.	Gibbs		
Attorney Dealest Mumb		ICDI I ODEOLIG	74				

Examiner Signature /Terra Cotta Gibbs/				Date Considered ation is in conformance with MPEP 609.	09/12/2008						
			EXAMINE	R SIGNATURE							
If you w	ish to a	idd add	ditional non-patent literature document cit	ation information please click the Add bu	itton						
	21		WONG, W. S. F., "Inhibitors of the tyrosine kinase signaling cascade for asthma," Current Opinion in Pharmacology (2005) 5:264-271.								
	20	incre	ELKOVSKI, J. et al., "An improved murine mo ased methacholine responsiveness following 49-856.								
	19		SALE, E. M. et al., "Use of an antisense strategy to dissect the role of MAP kinases in cellular signaling," Biochemical Society Transactions (1998) 26(3):S254.								

Standard ST.3). § For Japenese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TCG/